Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...

The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Hims & Hers beat first-quarter profit and revenue forecasts as sales more than doubled. However, the health and wellness ...

Hims & Hers Health (NYSE: HIMS), once a niche telehealth provider focused on men’s wellness, has rapidly transformed into a formidable player in the broader digital health ecosystem. HIMS stock has ...

Andrew Dudum; Chairman of the Board, Chief Executive Officer; Hims & Hers Health Inc Oluyemi Okupe; Chief Financial Officer; Hims & Hers Health Inc Good afternoon, ladies and gentlemen. Thank you for ...

Telehealth company Hims & Hers reported first-quarter results late Monday that beat Wall Street estimates. But parts of the ...

Hims & Hers Health Inc (HIMS) reports a 111% revenue surge and outlines future growth strategies amid expanding service ...

Express Scripts, Cigna, UnitedHealthcare, CVS Caremark and Optum Rx are among the payers that have added Yesintek to their ...